Literature DB >> 8018540

Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents.

M Smellie1, L R Kelland, D E Thurston, R L Souhami, J A Hartley.   

Abstract

The cellular pharmacology of a series of C8-linked pyrrolobenzodiazepine dimers with polymethylene linkers of n = 3-6 (compounds 1-4) has been studied in a range of human tumour cell lines. The four compounds showed the same pattern of relative activity in five ovarian carcinoma cell lines and one cervical carcinoma cell line with the order of IC50 values of 1 < or = 3 < 4 < 2, which correlated with the previously demonstrated DNA interstrand cross-linking ability of the compounds in plasmid DNA. In human leukaemic K562 cells the agents produced a block in the G2/M phase of the cell cycle characteristic of cross-linking drugs, and extensive interstrand cross-linking was observed in cells by alkaline elution with no evidence of single-strand breaks. Cross-links continued to increase up to 24 h following a 1 h exposure to drug, and no repair was evident by 48 h. In a series of ovarian and cervical carcinoma cell lines with acquired resistance to cisplatin no cross-resistance to the most potent compound 1 was observed in two lines whose major mechanism of resistance to cisplatin was reduced platinum transport. Cross-resistance to 1 was observed in a cell line (A2780cisR) possessing elevated glutathione, and depletion of intracellular glutathione using D,L-buthionine-S,R-sulphoximine (BSO) from 10.25 nmol to 2.8 nmol 10(-6) cells reduced the level of resistance from 11-fold to 2-fold compared with sensitive cells. Cross-linking in the resistant cells was restored to 80% of the level in the parent line by BSO pretreatment. There was also a correlation between glutathione levels and sensitivity to 1 measured in several other ovarian cell lines. Compound 1 also showed cross-resistance in the doxorubicin-resistant cell line 41MdoxR and partial cross-resistance in CH1doxR cells. Both these lines possess elevated levels of p170 glycoprotein. Following treatment with 6 microM verapamil, the resistance in these lines decreased almost 2-fold and 8-fold respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018540      PMCID: PMC2033325          DOI: 10.1038/bjc.1994.248

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Evaluation of the electrophilicity of DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines by HPLC.

Authors:  S J Morris; D E Thurston; T G Nevell
Journal:  J Antibiot (Tokyo)       Date:  1990-10       Impact factor: 2.649

2.  Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards.

Authors:  P M O'Connor; K W Kohn
Journal:  Cancer Commun       Date:  1990

3.  Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs.

Authors:  A Russo; W DeGraff; N Friedman; J B Mitchell
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

Review 4.  G2 block induced by DNA crosslinking agents and its possible consequences.

Authors:  J Konopa
Journal:  Biochem Pharmacol       Date:  1988-06-15       Impact factor: 5.858

5.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  Quantitative aspects of the formation and loss of DNA interstrand crosslinks in Chinese hamster cells following treatment with cis-diamminedichloroplatinum(II) (cisplatin). II. Comparison of results from alkaline elution, DNA renaturation and DNA sedimentation studies.

Authors:  M F Pera; C J Rawlings; J Shackleton; J J Roberts
Journal:  Biochim Biophys Acta       Date:  1981-09-28

7.  DNA-DNA interstrand crosslinking by dimethyanesulphonic acid esters. Correlation with cytotoxicity and antitumour activity in the Yoshida lymphosarcoma model and relationship to chain length.

Authors:  P Bedford; B W Fox
Journal:  Biochem Pharmacol       Date:  1983-08-01       Impact factor: 5.858

8.  Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks.

Authors:  C M Sorenson; A Eastman
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

9.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Authors:  C A Hills; L R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

10.  The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

Authors:  P Mistry; L R Kelland; G Abel; S Sidhar; K R Harrap
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  9 in total

Review 1.  Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines.

Authors:  Barbara Gerratana
Journal:  Med Res Rev       Date:  2010-06-13       Impact factor: 12.944

Review 2.  The clinical development of antibody-drug conjugates - lessons from leukaemia.

Authors:  Elias Jabbour; Shilpa Paul; Hagop Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2021-03-23       Impact factor: 66.675

3.  SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

Authors:  John A Hartley; Anzu Hamaguchi; Marissa Coffils; Christopher R H Martin; Marie Suggitt; Zhizhi Chen; Stephen J Gregson; Luke A Masterson; Arnaud C Tiberghien; Janet M Hartley; Christopher Pepper; Thet Thet Lin; Christopher Fegan; David E Thurston; Philip W Howard
Journal:  Cancer Res       Date:  2010-07-26       Impact factor: 12.701

4.  DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057.

Authors:  John A Hartley; Anzu Hamaguchi; Marie Suggitt; Stephen J Gregson; David E Thurston; Philip W Howard
Journal:  Invest New Drugs       Date:  2011-03-08       Impact factor: 3.850

5.  The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136.

Authors:  Peter H Clingen; Inusha U De Silva; Peter J McHugh; Farid J Ghadessy; Michael J Tilby; David E Thurston; John A Hartley
Journal:  Nucleic Acids Res       Date:  2005-06-08       Impact factor: 16.971

Review 6.  An overview of recent advances in duplex DNA recognition by small molecules.

Authors:  Sayantan Bhaduri; Nihar Ranjan; Dev P Arya
Journal:  Beilstein J Org Chem       Date:  2018-05-16       Impact factor: 2.883

Review 7.  Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.

Authors:  Antonio Ungaro; Marcello Tucci; Alessandro Audisio; Lavinia Di Prima; Chiara Pisano; Fabio Turco; Marco Donatello Delcuratolo; Massimo Di Maio; Giorgio Vittorio Scagliotti; Consuelo Buttigliero
Journal:  Cells       Date:  2022-02-25       Impact factor: 6.600

Review 8.  An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.

Authors:  Alberto D'Angelo; Robert Chapman; Marianna Sirico; Navid Sobhani; Martina Catalano; Enrico Mini; Giandomenico Roviello
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-11       Impact factor: 3.288

9.  Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.

Authors:  John A Hartley; Michael J Flynn; John P Bingham; Simon Corbett; Halla Reinert; Arnaud Tiberghien; Luke A Masterson; Dyeison Antonow; Lauren Adams; Sajidah Chowdhury; David G Williams; Shenlan Mao; Jay Harper; Carin E G Havenith; Francesca Zammarchi; Simon Chivers; Patrick H van Berkel; Philip W Howard
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.